摘要To the Editor:Sorafenib is a novel,orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase (FLT)-3-positive acute myeloid leukemia (AML) in recent years with favorable outcomes.Thyroiditis and hypothyroidism as side effects have been reported in treatment on renal cell cancer.[1] Here,we report a case of FLT3-internal tandem duplication (ITD)-positive AML,who developed subacute thyroiditis during treatment with sorafenib.Thyroiditis was controlled with sorafenib withdrawal and the use of dexamethasone.No thyroid dysfunction was detected under follow-up.Our experience shows that close monitoring of thyroid function is necessary in AML patients under sorafenib treatment.